![Pharis Mohideen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Pharis Mohideen
Technik-/Wissenschafts-/F&E-Leiter bei
DBV TECHNOLOGIES
Vermögen: 467 480 $ am 30.06.2026
Profil
Pharis Mohideen is currently Chief Medical Officer at DBV Technologies SA since 2019.
Former positions include Chief Medical Officer at Millendo Therapeutics, Inc. from 2014 to 2019; Vice President-Clinical Development at Shionogi, Inc. from 2012 to 2014; Global Head-Clinical Program at Novartis Oncology, Inc. from 2008 to 2012; Senior Director at Novartis International AG from 2006 to 2008; Principal at Bristol Myers Squibb Co.; Chief Medical Officer at Millendo Therapeutics US, Inc.; and Assistant Professor-Medicine at the University of Hawai'i at Hilo.
Education includes undergraduate, graduate, and doctorate degrees from the University of Hawai'i at Hilo and graduate studies at Vanderbilt University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DBV TECHNOLOGIES SA 0,05 % | 15.04.2026 | 144.995 ( 0,05 % ) | 467 480 $ | 30.06.2026 |
Aktive Positionen von Pharis Mohideen
| Unternehmen | Position | Beginn |
|---|---|---|
| DBV TECHNOLOGIES | Technik-/Wissenschafts-/F&E-Leiter | 22.07.2019 |
Ehemalige bekannte Positionen von Pharis Mohideen
| Unternehmen | Position | Ende |
|---|---|---|
| MILLENDO THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 12.07.2019 |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes antibiotics | Corporate Officer/Principal | 01.10.2014 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | 01.01.2012 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Corporate Officer/Principal | 01.01.2008 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Ausbildung von Pharis Mohideen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
26
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company which develops a novel treatment for adrenal cancer | Health Technology |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Hawai'i at Hilo
 University of Hawai'i at Hilo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes antibiotics | Health Technology |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Wählen Sie MarketScreener 
